Allison Bratzel
Stock Analyst at Piper Sandler
(4.67)
# 177
Out of 5,143 analysts
48
Total ratings
68.42%
Success rate
22.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Overweight | $28 → $30 | $8.29 | +261.88% | 1 | Nov 11, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $820 → $930 | $827.02 | +12.45% | 15 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $26 → $35 | $29.73 | +17.73% | 3 | Nov 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $70 → $77 | $81.79 | -5.86% | 3 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $82 → $102 | $105.06 | -2.91% | 3 | Nov 4, 2025 | |
| IOBT IO Biotech | Maintains: Overweight | $10 → $3 | $0.48 | +524.87% | 1 | Oct 22, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $52 → $51 | $47.76 | +6.78% | 4 | Sep 24, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $123.63 | -9.41% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $7.90 | +178.48% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $30.91 | +6.76% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $23.40 | +391.45% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $6 | $1.44 | +316.67% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $10.64 | +144.36% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $37.93 | -39.36% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $22.97 | -4.22% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.12 | +257.14% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $6.86 | +191.55% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $4.64 | +331.03% | 1 | Oct 13, 2023 |
MeiraGTx Holdings
Nov 11, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $8.29
Upside: +261.88%
argenx SE
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $827.02
Upside: +12.45%
Travere Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $26 → $35
Current: $29.73
Upside: +17.73%
Ionis Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $70 → $77
Current: $81.79
Upside: -5.86%
Incyte
Nov 4, 2025
Maintains: Overweight
Price Target: $82 → $102
Current: $105.06
Upside: -2.91%
IO Biotech
Oct 22, 2025
Maintains: Overweight
Price Target: $10 → $3
Current: $0.48
Upside: +524.87%
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $47.76
Upside: +6.78%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $123.63
Upside: -9.41%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $7.90
Upside: +178.48%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $30.91
Upside: +6.76%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $23.40
Upside: +391.45%
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $1.44
Upside: +316.67%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $10.64
Upside: +144.36%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $37.93
Upside: -39.36%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $22.97
Upside: -4.22%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.12
Upside: +257.14%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $6.86
Upside: +191.55%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $4.64
Upside: +331.03%